Abstract: SA-PO457
Better Anti-Spike IgG Antibody Response to SARS-CoV-2 Vaccine in Patients on Hemodiafiltration Than on Hemodialysis
Session Information
- Hemodialysis and Frequent Dialysis: Clearance, Technology, Infection
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Carrera, Fernando, DaVita, Leiria, Portugal
- Jacobson, Stefan H., Danderyd Hospital, Stockholm, Sweden
- Costa, Joana, DaVita, Leiria, Portugal
- Marques, Marco Alexandre, Affidea Laboratory, Lisbon, Portugal
- Ferrer, Francisco, DaVita, Leiria, Portugal
Background
The antibody response to SARS-CoV-2 vaccine in hemodialysis (HD) patients is diminished compared to healthy subjects. The aim of this study was to compare the presence of reactive SARS-CoV-2 antibodies in patients with high-flux HD and on-line hemodiafiltration (HDF) three and six months after the second dose of SARS-CoV-2 vaccine since previous studies indicate that a sustained antibody response correlate with protection from disease.
Methods
We included 216 HD patients of which 157 had on-line HDF and 59 high-flux HD and 46 health care workers as controls and studied the presence of reactive anti-spike IgG antibodies three and six months after the second dose of SARS-CoV-2 vaccine. Clinical features between the patient groups were similar, but patients with on-line HDF had significantly higher Kt/V.
Results
The percentage of participants with reactive antibodies was significantly lower in patients compared to controls, both three and six months after the second dose of vaccine. Furthermore, the proportion of patients with reactive anti-spike IgG ≥1.0 six months after the second dose of vaccine was significantly higher in patients with on-line HDF compared to in patients with high-flux HD. In logistic regression analyses adjusted for several clinical features, the variables associated with presence of reactive anti-spike IgG at three months after the second dose of vaccine were lower age, HDF treatment, not being obese and not having a previous solid organ transplant. The two variables with the strongest influence on the presence of reactive anti-spike IgG levels six months after the second dose of vaccine were treatment with on-line HDF and not having immunosuppressive therapy.
Conclusion
This is the first study to show that on-line HDF preserves the antibody response better than high-flux HD after vaccination with SARS-CoV-2 vaccine. Treatment strategies that sustain the vaccine response are essential to apply in this vulnerable group of patients.
Funding
- Private Foundation Support